Anti-Diabetes Drugs - South Africa

South Africa

The Anti-Diabetes Drugs market in South Africa is expected to witness a significant increase in revenue, with projections indicating a staggering amount of €280.10m by the year 2024.
Furthermore, this market is anticipated to display a promising annual growth rate (CAGR 2024-2029) of 6.92%, ultimately leading to a market volume of €391.30m by 2029.
When compared on a global scale, it is noteworthy that United States will generate the highest revenue in this sector, amounting to an impressive €35,090.00m in the year 2024.
South Africa is witnessing a growing demand for innovative anti-diabetes drugs due to the increasing prevalence of diabetes in the country.

Key regions: India, Australia, Italy, Europe, Brazil

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The demand for Anti-Diabetes Drugs in South Africa has been on the rise in recent years.

Customer preferences: The increasing prevalence of diabetes in South Africa has led to a growing demand for anti-diabetes drugs. Patients are seeking drugs that are effective in managing their condition while also being affordable. As a result, there has been a shift towards generic drugs that are more cost-effective than branded ones. Additionally, patients are increasingly looking for drugs that have fewer side effects and are easier to administer.

Trends in the market: The Anti-Diabetes Drugs market in South Africa is expected to see significant growth in the coming years due to a number of factors. Firstly, the increasing prevalence of diabetes in the country is a major driver of growth. In addition, the South African government has implemented a number of initiatives aimed at improving access to healthcare services, including diabetes treatment. This has led to an increase in the number of patients seeking treatment and has also increased the demand for anti-diabetes drugs. Another trend in the market is the increasing use of combination therapies. This involves combining two or more drugs to achieve better glycemic control. Combination therapies are becoming more popular as they are often more effective than single drug therapies and can also reduce the risk of side effects.

Local special circumstances: South Africa has a high prevalence of diabetes, with an estimated 4.6 million people living with the condition. This is due to a number of factors, including a rapidly growing population, a high prevalence of obesity, and a lack of physical activity. The country also has a high prevalence of HIV/AIDS, which can increase the risk of developing diabetes.

Underlying macroeconomic factors: South Africa's economy has been struggling in recent years, with slow economic growth and high levels of unemployment. This has had an impact on the Anti-Diabetes Drugs market, as many patients are unable to afford expensive branded drugs. As a result, there has been a shift towards generic drugs, which are more affordable. In conclusion, the Anti-Diabetes Drugs market in South Africa is expected to see significant growth in the coming years due to the increasing prevalence of diabetes and the government's efforts to improve access to healthcare services. Patients are increasingly looking for drugs that are effective, affordable, and have fewer side effects. Combination therapies are also becoming more popular. However, the slow economy and high levels of unemployment are impacting the market, with many patients unable to afford expensive branded drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.